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Objective: High-dose preoperative amiodarone therapy has been implicated 
as a risk factor for serious complications after cardiac operations. To 
investigate the effect of preoperative low-dose amiodarone treatment on 
early postoperative outcome after cardiac operations, we prospectively 
studied 88 patients. Methods: Forty-four patients were receiving amioda- 
rone (mean daily dose - standard deviation, 205 - 70 mg/day) and 44 
patients were controls matched in pairs. The following parameters were 
recorded after the operation in all patients: (1) the ratio of oxygen tension 
to inspired oxygen fraction on arrival in the intensive care unit and 2, 4, 6, 
10, 14, 18, and 22 hours thereafter; (2) the occurrence of acute respiratory 
distress syndrome; (3) early postoperative cardiac complications; and (4) 
the type and number of inotropic agents or vasopressors (or both) needed. 
Results: No difference in the ratio of oxygen tension to inspired oxygen 
fraction was noted at the various time intervals between amiodarone- 
treated patients and control patients. Overall, only one patient had acute 
respiratory distress syndrome in the amiodarone group, but he had 
multiple other factors known to predispose to acute lung injury. Several 
cardiac complications, uch as pulmonary edema, temporary pacing, and 
need for intraaortic balloon pump counterpulsation, were observed more 
frequently in amiodarone-treated patients than in control patients. In 
addition, amiodarone-treated patients required more frequent inotropic 
support (73% vs 43%,p = 0.003) and more inotropic drugs or vasopressors 
(or both) per patient han did control patients (1.4 _+ 1.1 vs 0.6 --- 0.8, p = 
0.002). Conclusion: Preoperative low-dose amiodarone therapy does not 
seem to be related to significant postoperative lung toxicity, but it is 
associated with various cardiac complications and an increased need for 
more intense inotropic support after cardiac operations. These findings 
may be related to the drug's depressant effect on the myocardium. 
(J Thorac Cardiovasc Surg 1997;114:31-7) 
A miodarone is an iodinated benzofuran derivative that has been proved effective in the control of 
supraventricular nd ventricular arrhythmias refrac- 
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tory to other antiarrhythmic drugs. 1 Its use has been 
complicated by the frequent development of adverse 
effects, the most serious of which is pulmonary 
toxicity occurring in 5% to 10% of patients, rare 
proarrhythmic effects, worsening of cardiac failure, 
conduction disturbances, and hepatic dysfunc- 
tion.Z, 3 Surgical intervention i  patients treated with 
amiodarone is commonly required, and several re- 
ports have suggested that these patients may be at 
particular isk for cardiopulmonary complications, 
including rapidly progressive adult respiratory dis- 
tress syndrome (ARDS). Such complications have 
been described after cardiac operations or endocar- 
dial resection, 4-9 lung resection, 1° operations for 
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Table I. Perioperative data 
Amiodarone Control 
group group 
(n=44) (n=44) p Value 
Type of operation (No.) 
CABG 28 
VR 9 
CABG+VR 5 
ASD 1 
ALV 1 
Surgical teams 
Team 1 (No. of patients) 25 
Team 2 (No. f patients) 13 
Team 3 (No. of patients) 6 
Bypass time (rain) 107 -- 
Crossclamp time (min) 61 - 
28 
9 
5 
1 
1 
25 
13 
6 
52* 94 _+ 32* 0.07 
40* 55 -+ 28* 0.6 
ALV, Aneurysmectomy of the left ventricle; ASD, atrial septal defect; 
CABG, coronary artery bypass grafting; VR, valve replacement. 
*Mean +- standard deviation. 
implantation of an automatic ardioverter-defibril- 
lator,9, 11 pulmonary angiography, 12and even after 
abdominal surgery. 4 The side effects of amiodarone, 
especially pulmonary toxicity, are thought o be dose 
and time relatedl3; indeed, in all previous studies in 
which amiodarone toxicity has been documented, 
amiodarone-treated patients had received high 
maintenance doses (375 to 685 mg/day), usually for 
a prolonged time. Low-dose amiodarone therapy 
(200 to 300 mg/day) is mostly used in Europe, and it 
has been shown to be safe and effective. 14 The 
current study was undertaken to prospectively eval- 
uate the early postoperative cardiopulmonary com- 
plications of patients undergoing cardiac operations 
who had received a low-dose amiodarone regimen 
in the preoperative period. 
Methods 
Study population. Between October 1994 and March 
1996, three different surgical teams performed cardiac 
operations on 1971 patients at Onassis Cardiac Surgery 
Center. Data were collected prospectively from all con- 
secutive patients (n = 44) who were receiving amiodarone 
before the operation, aswell as from control patients who 
were operated on during the same time interval but had 
not received amiodarone. Control and amiodarone- 
treated patients were matched in pairs, in terms of the 
following parameters: age (mean -+ standard deviation 
[SD], 61 -+ 9 vs 61 +_ 9 years); sex (88% male in each 
group); smoking history (85% smokers in each group); 
extent of cardiac disease (single-, double-, or triple-vessel 
disease, 7% vs 9%, 43% vs 31%, and 46% vs 59%); New 
York Heart Association classification as regards angina 
(class I, 45% vs 39%; class II, 38% vs 43%; and classes III 
to IV, 17% vs 18%), and preoperative l ft ventricular 
ejection fraction (44% -+ 12% vs 41% -+ 13%). On the 
basis of routine clinical examination, o patient in either 
group was preoperatively believed to have chronic ob- 
structive pulmonary disease. The two groups were also 
matched for type of operation, the surgical team perform- 
ing the operation, and bypass and aortic crossclamp times 
(Table I). Treating physicians were not aware that the 
patients were included in a clinical study. 
In the preoperative period, patients were treated with 
various medications, uch as digoxin, /3-blockers, angio- 
tensin-converting enzyme inhibitors, calcium channel 
blockers, nitrates, antiplatelet agents, and diuretics. Ami- 
odarone-treated patients were using /3-blockers less fre- 
quently than control patients (25% vs 53%, p = 0.009). 
The duration of amiodarone therapy ranged from 7 to 
1440 days (mean -+ SD, 231 - 269 days), the daily 
maintenance dose from 100 to 420 mg (mean -+ SD, 205 -+ 
70 mg), and the total dose from 3 to 430 gm (mean +- SD, 
45 _+ 68 gin). Fifteen patients were receiving amiodarone 
for atrial fibrillation, 14 for refractory multifocal prema- 
ture ventricular beats, three for previous episodes of 
ventricular tachycardia, four for previous ventricular fi- 
brillation, two for atrial flutter, and six for ill-defined 
reasons. None of the amiodarone-treated patients had 
apparent pulmonary toxicity and none had discontinued 
his or her treatment before the operation. 
Cardiopulmonary b pass with a membrane oxygenator 
was applied with moderate systemic hypothermia (28 ° to 
30 ° C) and hemodilution at a flow rate of 2 L/min per 
square meter. Ninety-one percent of the amiodarone- 
treated patients and 93% of the control patients received 
blood cardioplegia, whereas 7% and 5% of patients, 
respectively, received cold crystalloid cardioplegia (St. 
Thomas' Hospital II solution). In one patient in each 
group, cardiac arrest wasachieved with fibrillation without 
cardioplegia. 
Protocol. The following parameters were recorded af- 
ter the operation in all patients: 
1. The ratio of oxygen tension to inspired oxygen 
fraction (Poz/Fio 2 ratio) on arrival in the intensive care 
unit (ICU) and 2, 4, 6, 10, 14, 18, and 22 hours after the 
operation while in the ICU, to index the degree of 
hypoxemia. 
2. The occurrence of adult respiratory distress syn- 
drome (ARDS). Amiodarone-related ARDS was defined 
according to the Joint European-American Consensus 
Conference on ARDS: (a) oxygenation: Poz/F io  2 ----- 200, 
regardless of positive end-expiratory pressure; (b) chest 
x-ray film: bilateral infiltrates een on frontal chest x-ray 
film; and (c) pulmonary artery wedge pressure: 18 mm Hg 
or less when measured or no clinical evidence of left atrial 
hypertension according to chest x-ray film and other 
clinical dataY 
3. The postoperative cardiac complications observed. 
4. The type and number of inotropic drugs or vasopres- 
sots (or both) administered. These agents were intro- 
duced in the operating room or in the ICU (or both) on 
the basis of the following criteria: (a) difficulty to wean 
from cardiopulmonary bypass; (b) hypotension (mean 
systemic arterial pressure < 60 mm Hg) unresponsive to 
fluid administration; and (c) cardiac index < 2.2 L/min per 
square meter after optimization of volume status, heart 
rate, and rhythm. 
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Table II. Postoperative cardiac complications 
Amiodarone Control 
group group 
(n=44) (n=44) 
Atrial fibrillation 6 2 
Ventricular tachycardia 0 1 
Temporary pacing 5 2 
Intraaortic balloon pump 2 0 
Myocardial infarction 2 0 
Pulmonary edema 4 0 
Total 19" 5* 
*p = 0.004. 
Thermodilution cardiac output catheters (Swan-Ganz 
catheters, Baxter Healthcare Corp., Edwards Division, 
Santa Ana, Calif.) were inserted routinely before the 
operation if the preoperative ejection fraction was less 
than 35%, if left main coronary artery disease was present, 
or if patients had had a recent myocardial infarction. In 
addition, athermodilution catheter was introduced during 
the operation or in the ICU for difficulties in restoring 
arterial blood pressure or in monitoring inotropic support. 
In our institution the first-line inotropic agents used 
are dobutamine oradrenaline, depending on the patient's 
response. If cardiac output or blood pressure remain 
marginal, despite moderate doses of one drug (dobut- 
amine 8 to 10 txg/kg per minute, adrenaline 0.3 /xg/kg 
per minute), the second is added. In patients with pulmo- 
nary hypertension we usually use milrinone, alone or in 
combination with the aforementioned inotropic drugs. 
Dopamine is often used in renal dose (2 to 3 txg/kg per 
minute), unless severe hypotension ensues. Vasopressors 
(norepinephrine or phenylephrine hydrochloride [Neo- 
Synephrine]) are used during the rewarming period in the 
ICU for significant hypotension with low systemic vascular 
resistance unresponsive to fluid resuscitation. If hemody- 
namic stability cannot be achieved with inotropic support, 
an intraaortic balloon pump is inserted. 
Statistical analysis. Values for continuous variables 
are expressed as the mean -+ SD of the mean. So that 
comparisons could be made between amiodarone-treated 
patients and control patients, Student's t test, paired t test, 
the Wilcoxon matched-pairs signed rank test, the Mann- 
Whitney rank sum test, and the Mantel-Haenszel test 
were performed where appropriate with the use of Sigma- 
stat (Jandel Corporation, San Rafael, Calif.) and SPSS 
statistical software (SPSS, Inc., Chicago, Ill.). Differences 
were considered statistically significant if the p value was 
less than 0.05. 
Results 
Postoperative oxygenation ARDS--Iung com- 
plications. No difference in oxygenation was ob- 
served between amiodarone-treated patients and 
control patients, as expressed by the Po2/Fio 2 ratio, 
at the various time intervals (Fig. 1). Overall, only 
one patient had ARDS: he had a long-standing 
history of coronary artery disease, his preoperative 
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Fig. 1. PoJFio2 ratio in amiodarone-treated control pa- 
tients on arrival in the ICU and at various time intervals 
after the cardiac operation (mean +_ SD). Not all patients 
stayed in the ICU for the entire 22-hour period. 
left ventricular ejection fraction was 50%, and he 
had been receiving amiodarone (200 mg/day) for 
about 3 months before the operation for atrial 
fibrillation. This patient had an extensive intra- 
operative myocardial infarction necessitating a
prolonged bypass time (6 hours) and multiple trans- 
fusions. Postoperatively, he required multiple ino- 
tropic drugs and intraaortic balloon pump support 
to maintain adequate blood pressure. He remained 
intubated for 10 days requiring high concentrations 
of inspired oxygen (Fio2) and finally died of multi- 
organ failure and sepsis. 
Three patients, all in the amiodarone group, had 
left lower lobe atelectasis on radiologic examination, 
which resolved after intense physiotherapy and 
bronchodilator use. 
Cardiac complications. Overall, postoperative 
cardiac complications observed in the ICU (Table 
II) were more frequent in the amiodarone-treated 
group than in the control group (19 vs 5 complica- 
tions, p = 0.004, X 2 = 8.45, odds ratio [OR] = 5.67, 
and 95% confidence intervals (CI) of OR 1.76 to 
18.25). Four of the 44 amiodarone-treated patients 
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Fig. 2. Percent of patients with inotropic agents or vaso- 
pressors, dobu, Dobutamine; adre, adrenaline; dopa, do- 
pamine; milr, milrinone; vaso, vasopressors. 
had pulmonary edema. Two of them had this com- 
plication while in the ICU and had high pulmonary 
capillary wedge pressure (>20 mm Hg). The other 
two patients were readmitted from the ward to the 
intermediate care unit, 2 and 3 days after the 
operation, with dyspnea nd tachypnea, rales, dis- 
tention of internal jugular veins, hypoxemia (Po2 50 
and 55 mm Hg, respectively, with the patients 
breathing room air), and radiologic findings consis- 
tent with mild pulmonary interstitial edema (redis- 
tribution of blood flow and Kerley B lines). We did 
not insert a thermodilution catheter in these two 
patients, because they were in hemodynamically 
stable condition and showed prompt response to 
treatment with oxygen and diuretics. None needed 
intubation and mechanical ventilatory support, and 
they were discharged to the ward after 1 and 2 days, 
respectively, without experiencing any further com- 
plications. They did not need bronchodilators or
steroids at any time. 
Perioperative support with inotropic drugs or 
vasopressors (or both). More amiodarone-treated 
patients required inotropic drugs or vasopressors 
(or both) than did control patients (73% of patients 
vs 43% of patients, p = 0.003, ~ = 8.65, OR = 5.56, 
and 95% CI of OR 1.77 to 17.42). All inotropic 
agents and vasopressors were used more frequently 
in amiodarone-treated patients (Fig. 2), but only the 
use of dobutamine reached statistical significance 
(55% of patients vs 25% of patients, p = 0.008, )(2 = 
7.04, OR = 3.8, and 95% CI of OR 1.42 to 10.19). 
The duration of dobutamine infusion was longer in 
the amiodarone group (mean 31 _+ 34 hours, median 
20 hours, 25th to 75th percentiles 15 to 40, vs mean 
15 _+ 13 hours, median 15 hours, 25th to 75th 
percentiles 2 to 20 hours, p = 0.049), as was the 
maximum dose administered (mean 7 -+3 ~g/kg per 
minute, median 5 txg/kg per minute, 25th to 75th 
percentiles 4 to 8 ~g/kg per minute, vsmean 4 _+ 1 
txg/kg per minute, median 4 ~g/kg per minute, 25th 
to 75th percentiles 3 to 5 ~g/kg per minute, p = 
0.009). More inotropic agents and vasopressors per 
patient were required in the amiodarone group than 
in the control group (mean 1.4 + 1.1, median 1, 25th 
to 75th percentiles 0 to 2, vs mean 0.6 _+ 0.8, median 
0, 25th to 75th percentiles 0 to 1, p = 0.002). 
In most cases, in 88% and 84% for amiodarone 
and control groups, respectively, inotropic agents 
were introduced in the operating room. Thirty-five 
of the 51 patients who received inotropic drugs had 
a thermodilution catheter. The mean cardiac index 
and systemic vascular esistance measured before 
sternotomy were 2.2 _ 0.6 L/min per square meter 
and 1333 _+ 580 dynes • sec" cm -5, respectively. 
Except for the patient who died and his matched 
control, the mean postoperative intubation time was 
16 -+ 11 hours in the amiodarone-treated group and 
12 _ 4 hours in the control group (median 12 hours, 
25th to 75th percentiles 11 to 18 hours, vs median 11 
hours, 25th to 75th percentiles 10 to 14 hours, p = 
0.03), whereas the time spent in the ICU was 39 -+ 
30 and 27 _+ 14 hours (median 28 hours, 25th to 75th 
percentiles 24 to 43 hours, vs median 24 hours, 25th 
to 75th percentiles 19 to 28 hours, p = 0.02). 
However, causes of prolonged intubation and ICU 
stay were not related to the use of amiodarone and 
included bleeding with surgical reexploration, shiv- 
ering with metabolic acidosis necessitating pro- 
longed sedation and muscle relaxation, agitation, 
and impaired consciousness. The mean hospital stay 
both in the amiodarone and in the control group was 
8 _+ 2 days (median 8 days, 25th to 75th percentiles 
7 to 9 days, vs median 7 days, 25th to 75th percen- 
tiles 6 to 8 days, p = 0.09). 
Discussion 
In this prospective study we found that patients 
receiving long-term low-dose amiodarone therapy 
did not have significant lung toxicity after cardiac 
operations, as assessed by impairment in oxygen- 
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ation or occurrence of ARDS. However, they had 
more frequent cardiac complications and required 
more intense inotropic support in the early postoper- 
ative period than did matched paired control patients. 
Amiodarone is an effective antiarrhythmic agent 
with potentially serious ide effects, which may limit 
its clinical utility. 1' 2 Of particular interest are case 
reports and small series of patients uggesting that 
amiodarone can induce significant pulmonary and 
hemodynamic complications in patients undergoing 
various cardiac operations. 16Acute lung injury, with 
all the characteristics of ARDS, may occur in the 
immediate postoperative p riod or occasionally 3 to 
5 days after the operation 8'10, 11, 17 and results in 
prolonged ventilatory support and high mortali- 
ty.4, 7, 8, 10 Although the mechanism by which amio- 
darone may elicit acute lung toxicity after cardiac 
operations remains unknown, prolonged pump-oxy- 
genator time, anesthetic agents, congestive heart 
failure, preoperative amiodarone pulmonary toxic- 
ity, superimposed pulmonary infection, and expo- 
sure to high Fio 2 have all been implicated as predis- 
posing factors, is' 19 Most previous tudies examining 
amiodarone's adverse effects after cardiac opera- 
tions are retrospective and include patients receiv- 
ing high preoperative doses of the drug (350 to 720 
mg/day), for prolonged time intervals. 
Our study was prospective and involved, to our 
knowledge, the largest number of amiodarone- 
treated patients who underwent cardiac operations. 
Our patients were matched for age, sex, smoking 
history, ejection fraction, type of operation per- 
formed, duration of cardiopulmonary bypass, and 
duration of aortic crossclamping. We did not find 
any difference in the oxygenation status between 
amiodarone-treated patients and control patients 
during a 22-hour interval after the operation. Al- 
though we did not routinely record our patients' 
arterial blood gases after they left the ICU, we 
believe we would have detected any serious respira- 
tory complication thereafter, because such compli- 
cations would have resulted in readmission to the 
ICU or intermediate care unit. Only one of the 44 
amiodarone-treated patients had ARDS, but he had 
numerous other predisposing factors known to con- 
tribute to the development of acute lung injury. Our 
finding that lung toxicity is not as frequently ob- 
served as described in previous tudies is probably 
related to the low-dose regimen (205 mg/day) and 
the low total dose of amiodarone (less than 50 gin) 
administered. However, this finding should be cau- 
tiously interpreted, because our study involves a 
relatively small number of patients and the possibil- 
ity of a type II error cannot be excluded, given the 
very low incidence (1/88) of ARDS in our study. Our 
study did not investigate xtensively the occurrence 
of atelectasis in the two groups of patients by 
examining chest x-ray films according to a certain 
atelectasis score. We identified only three amioda- 
rone-treated patients who had lobar atelectasis ne- 
cessitating specific therapy. Postoperative atelectasis 
after cardiac operations has been associated with 
many other factors, such as decreased clearance of 
secretions, decreased mobility, gastric distention, 
intraoperative lung contusion, or phrenic nerve hy- 
pothermic injury. 2° Therefore we believe that fur- 
ther studies are needed to test the hypothesis that 
postoperative atelectasis might be related to the 
preoperative use of amiodarone. 
The cardiovascular complications of amiodarone 
may result from the accentuation of its pharmaco- 
logic, hemodynamic, and electrophysiologic actions. 
The drug has an a-antagonist and a /3-antagonist 
activity, which results from inhibition of adenyl 
cyclase formation, reduction in the number of/3-ad- 
renergic receptors, and inhibition of the inward 
calcium ion current. 21 From the hemodynamic point 
of view, amiodarone increases coronary blood flow 
by dilating coronary arteries, and it decreases sys- 
temic blood pressure and afterload by peripheral 
arterial vasodilation. In addition, amiodarone may 
reduce ventricular contractility through a mild direct 
negative inotropic effect on the myocardium. 1' 3 An 
increased incidence of postoperative low cardiac 
output syndrome has been observed in amiodarone- 
treated patients who undergo cardiac operations, 
and the drug has been implicated as a possible 
etiologic factor. 22 Other studies have shown that 
these patients more often required intraaortic bal- 
loon pump support o be weaned from cardiopul- 
monary bypass and that, in rare cases, angiotensin, a 
potent arterial vasoconstrictor, was used .  23 In terms 
of electrophysiology, amiodarone reduces sinus 
node and junctional automaticity, increases the con- 
duction time and refractoriness of the atrioventric- 
ular node, prolongs the QT interval, and reduces 
conduction velocity in the myocardium and Purkinje 
tissue. 24 Accordingly, postoperative atropine-resis- 
tant or/3-agonist-resistant bradycardia or complete 
atrioventricular block (or both), requiring atrioven- 
tricular sequential pacing, have been described in 
amiodarone-treated patients. Therefore some inves- 
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tigators suggest hat the drug has to be used pru- 
dently in candidates for cardiac operations. 5' 6 
In accordance with the aforementioned reports, 
our study demonstrates that patients who receive 
low-dose amiodarone in the preoperative period are 
more likely to have postoperative cardiac omplica- 
tions, such as pulmonary edema, need for temporary 
pacing, and intraaortic balloon pump counterpulsa- 
tion. These findings are even more significant when 
the less frequent preoperative use of/g-blockers by 
our patients is taken into account. 
Acute reversible myocardial dysfunction occurs 
commonly after elective cardiac operations. This 
condition is termed "stunned myocardium" and has 
been associated with the ischemic injury induced by 
cardioplegia--the cardioplegic arrest and the reper- 
fusion injury. This situation has been described even 
in patients with good preoperative l ft ventricular 
performance. The appropriate treatment is the in- 
troduction of inotropic drugs. 25 Breisblatt and asso- 
ciates 26 reported that 71% of their patients needed 
inotropic drugs in the postoperative p riod, despite 
a mean preoperative ejection fraction of 58%. Roys- 
ter and coworkers 27 defined a critical value of 
ejection fraction, 55%, which differentiated patients 
who require more intense inotropic support from 
those who do not. In the present study, amiodarone- 
treated patients required inotropic agents more 
often than their matched controls, with dobutamine 
reaching statistical significance, because this is the 
first-line inotropic drug used in our institution. 
Therefore our data suggest that preoperative amio- 
darone therapy may accentuate ransient myocardial 
stunning after cardiac operations. In contrast, in a 
recent study, Mickleborough and associates s found 
that amiodarone-treated patients undergoing car- 
diac operations did not differ from control patients 
in terms of inotropic support. However, they re- 
ported a trend toward more frequent adrenaline use 
in the amiodarone group to treat low systemic 
vascular esistance and to maintain adequate perfu- 
sion pressures. 8 In that study the impact of amioda- 
rone on postoperative myocardial depression, based 
on the need for inotropic support, is difficult to 
assess because all patients had poor preoperative 
left ventricular function (ejection fraction 23% to 
33%) and long pump times (246 to 254 minutes), 
and the majority would have needed inotropic drugs 
anyway. Additionally, Mickleborough and associ- 
ates 8 used inotropic agents in a slightly higher 
percentage than we did (83% vs 74% of amioda- 
rone-treated and non-amiodarone-treated groups, 
respectively, received dopamine with or without 
dobutamine and 14% vs 0%, respectively, received 
adrenaline). With this high percentage and with 
their smaller patient numbers, statistical significance 
would be more difficult to achieve. 
In conclusion, in contrast to previous reports that 
revealed an association between high-dose amioda- 
rone treatment and ARDS, long-term low-dose 
amiodarone therapy does not seem to be related to 
a high risk for acute lung toxicity after cardiac 
operations. However, it is associated with a more 
prolonged intubation time and ICU stay and an 
increased incidence of postoperative cardiac com- 
plications. In addition, our study is the first to point 
out that low-dose amiodarone may increase the 
need for inotropic support after cardiac operations. 
These findings may be ascribed to the accentuation 
of amiodarone's adverse lectrophysiologic and he- 
modynamic actions after cardiac surgery. Therefore 
we suggest hat amiodarone should be used with 
caution in candidates for cardiac operations, even if 
the drug is administered in a low dose. 
We thank Dr. Anastasia Tzonou, Associate Professor of 
Epidemiology and Statistics, University of Athens, Medi- 
cal School, for her contribution to the statistical nalysis. 
REFERENCES 
1. Mason JW. Amiodarone. N Engl J Med 1987;316:455-66. 
2. Marchlinski FE, Gansler TS, Waxman HL, Josephson ME. 
Amiodarone pulmonary toxicity. Ann Intern Med 1982;97: 
839-45, 
3. Podrid PJ. Amiodarone: Reevaluation of an old drug. Ann 
Intern Med 1995;122:689-700. 
4. Kay GN, Epstein AE, Kirklin JK, Diethelm AG, Graybar G, 
Plumb VJ. Fatal postoperative amiodarone pulmonary toxic- 
ity. Am J Cardiol 1988;62:490-2. 
5. Gallagher JD, Lieberman RW, Meranze J, Spielman SR, 
EUison N. Amiodarone-induced complications during coro- 
nary artery surgery, Anesthesiology 1981;55:186-8. 
6. Terada Y, Mitsui T, Yamaguchi I. Conduction disturbances 
after open heart surgery in a patient receiving amiodarone. 
Ann Thorac Surg 1994;58:1213-4. 
7. Kupferschmid JP, Rosengart TK, Mclntosh CL, Leon MB, 
Clark RE. Amiodarone-induced omplications after cardiac 
operations for obstructive hypertrophic ardiomyopathy. 
Ann Thorac Surg 1989i48:359-64. 
8. Mickleborough LL, Maruyama H, Mohamed S, et al. Are 
patients receiving amiodarone at increased risk for cardiac 
operations. Ann Thorac Surg 1994;56:622-9. 
9. Greenspon A J, Kidwell GA, Hurley W, Mannion J. Amio- 
darone-related postoperative adult respiratory distress syn- 
drome, Circulation 1991;84:407-15. 
10. Van Mieghem W, Coolen L, Malysse I, Lacquet LM, Deneffe 
GJD, Demets MGP. Amiodarone and the development of
ARDS after lung surgery., Chest 1994;105:1642- 
11. Hawthorne HR, Wood MA, Stambler BS, Damiano RJ, 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 114, Number 1 
Dimopoulou et aL 3 7 
Ellenbogen KA. Can amiodarone pulmonary toxicity be 
predicted in patients undergoing implantable cardioverter 
defibrillator implantation? Pace 1993;16:2241-49. 
12. Wood DL, Osborn MJ, Rooke J, Holmes DR. Amiodarone 
pulmonary toxicity: report of two cases associated with 
rapidly progressive fatal adult respiratory distress syndrome 
after pulmonary angiography. Mayo Clin Proc 1985;60:601-3. 
13. Martin WJ. Mechanisms of amiodarone pulmonary toxicity. 
In: Cooper JAD, editor. Drug-induced pulmonary disease, 
Clinics in Chest Medicine, WB Saunders, 1990;11:131-8. 
14. Kowey PR, Friehling TD, Marinchak RA, Sulpizi AM, 
Stohler JL. Safety and efficacy of amiodarone. The low-dose 
perspective. Chest 1988;93:54-9. 
15. Bernard GR, Artigas A, Brigham KL, et al. and the Consen- 
sus Committee The American-European Consensus confer- 
ence on ARDS. Definitions, mechanisms, relevant outcomes, 
and clinical coordination. Am J Respir Crit Care Med 
1994;149:818-24. 
16. Tuzcu EM, Maloney JD, Sangani BH, et al. Cardiopulmo- 
nary effects of chronic amiodarone therapy in the early 
postoperative course of cardiac surgery patients. Cleve Clin 
J Med 1987;54:491-7. 
17. Herndon JC, O'Cook AO, Ramsay MAAE, Swygert TH, 
Capehart J. Postoperative unilateral pulmonary edema: pos- 
sible amiodarone pulmonary toxicity. Anesthesiology 1993; 
76:308-12. 
18. Nalos PC, Kass RM, Gang ES, Fishbein MC, Mandel WJ, 
Peter T. Life-threatening postoperative pulmonary complica- 
tions in patients with previous amiodarone pulmonary toxic- 
ity undergoing cardiothoracic operations. J Thorac Cardio- 
vasc Surg 1987;93:904-12. 
19. Donica SK, Paulsen AW, Simpson BR, et al. Danger of 
amiodarone therapy and elevated inspired oxygen concentra- 
tions in mice. Am J Cardiol 1996;77:109-10. 
20. Wilcox P, Baile EM, Hards J, Muller NL, Dunn L, Pardy RL, 
Parre PD. Phrenic nerve function and its relationship to 
atelectasis after coronary artery bypass surgery. Chest 1988; 
93:693-8. 
21. Singh BN, Jewitt DE, Downey JM, Kirk ES, Sonnenblick EH. 
Effects of amiodarone and L8040, novel antianginal and 
antiarrhythmic drugs on cardiac and coronary hemodynamics 
and on cardiac intracellular potentials. Clin Exp Pharmacol 
Physiol 1976;3:427-42. 
22. MacKinnon G, Landymore R, Marble A. Should oral amio- 
darone be used for sustained ventricular tachycardia in 
patients requiring open-heart surgery? Can J Surg 1983;26: 
355-7. 
23. Lieberman BA, Teasdale SJ. Anesthesia nd amiodarone. 
Can Anaesth Soc J 1985;32:629-38. 
24. Torres V, Tepper D, Flowers D, et al. QT prolongation and 
the antiarrhythmic efficacy of amiodarone. J Am Coil Cardiol 
1986;7:142-7. 
25. Doyle AR, Dhir AK, Moors AH, et al. Treatment of periop- 
erative low cardiac output syndrome. Ann Thorac Surg 
1995;59:$3-11. 
26. Breisblatt WM, Stein KL, Wolfe CJ, et al. Acute myocardial 
dysfunction and recovery: a-common occurrence after coro- 
nary bypass surgery. J Am Coil Cardiol 1990;15:1261-9. 
27. Royster RL, Butterworth JF, Prough DS, et al. Preoperative 
and intraoperative predictors of inotropic support and long- 
term outcome in patients having coronary artery bypass 
grafting. Aalesth Analg 1991;72:729-360. 
